Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Low booster uptake in cancer patients despite health benefits.

Autor: Figueiredo JC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.; Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Levy J; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Choi SY; Biostatistics Shared Resource, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Xu AM; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Merin NM; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Hamid O; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA 90025, USA., Lemos T; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Nguyen N; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Nadri M; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Gonzalez A; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Mahov S; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Darrah JM; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Gong J; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Paquette RL; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Mita AC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Vescio RA; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Salvy SJ; Research Center for Health Equity, Department of Biomedical Sciences, Los Angeles, CA 90048, USA., Mehmi I; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA 90025, USA., Hendifar AE; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Natale R; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Tourtellotte WG; Department of Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Ramanujan VK; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Huynh CA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Sobhani K; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Reckamp KL; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA., Merchant AA; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Publikováno v: IScience [iScience] 2024 Jul 26; Vol. 27 (9), pp. 110596. Date of Electronic Publication: 2024 Jul 26 (Print Publication: 2024).

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.

Autor: Merryman RW; Division of Hematologic Malignancies and., Redd RA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL., Chavez J; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL., Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Darrah JM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.; Cedars-Sinai Medical Center, Los Angeles, CA., Rao U; Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Byrne MT; Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Bond DA; Division of Hematology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University Hospital, Columbus, OH., Maddocks KJ; Division of Hematology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University Hospital, Columbus, OH., Spinner MA; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA., Advani RH; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA., Ballard HJ; Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA., Svoboda J; Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA., Singh AK; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS., Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI., Ramchandren R; Division of Hematology/Oncology, University of Tennessee School of Medicine, Knoxville, TN., Romancik J; Department of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, GA., Cohen JB; Department of Hematology and Medical Oncology, Emory University-Winship Cancer Institute, Atlanta, GA., Frigault MJ; Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA., Chen YB; Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA., Serritella AV; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Kline J; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Ansell S; Division of Hematology, Mayo Clinic, Rochester, MN., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL., Rahimian M; Beth Israel Deaconess Medical Center, Boston, MA., Joyce RM; Beth Israel Deaconess Medical Center, Boston, MA., Shah M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., David KA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Park S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC., Beaven AW; Division of Hematology, University of North Carolina, Chapel Hill, NC., Habib A; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Nakhoda S; Division of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA; and., Khan N; Division of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA; and., Lynch RC; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Ho VT; Division of Hematologic Malignancies and., LaCasce A; Division of Hematologic Malignancies and., Armand P; Division of Hematologic Malignancies and., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

Publikováno v: Blood advances [Blood Adv] 2021 Mar 23; Vol. 5 (6), pp. 1648-1659.

Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm.

Autor: Darrah JM; Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA., Stefani MR, Moghaddam B

Publikováno v: Behavioural pharmacology [Behav Pharmacol] 2008 May; Vol. 19 (3), pp. 225-34.